Karen E. Gascoigne
Affiliations: | 2005-2008 | Faculty of Life Sciences | University of Manchester, Manchester, England, United Kingdom |
| 2009-2014 | Massachusetts Institute of Technology, Cambridge, MA, United States | ||
| 2014- | Genetech, Kota Kinabalu, Sabah, Malaysia |
Google:
"Karen Gascoigne"Parents
Sign in to add mentor| Stephen S. Taylor | grad student | 2005-2008 | University of Manchester |
| Iain M. Cheeseman | post-doc | 2009-2014 | MIT |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Raisner R, Bainer R, Haverty PM, et al. (2020) Super-enhancer acquisition drives oncogene expression in triple negative breast cancer. Plos One. 15: e0235343 |
| de Almeida Nagata DE, Chiang EY, Jhunjhunwala S, et al. (2019) Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Reports. 27: 269-281.e4 |
| Raisner R, Kharbanda S, Jin L, et al. (2018) Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Reports. 24: 1722-1729 |
| Chang Y, Woessner DW, Lin W, et al. (2018) Abstract IA12: Modeling and targeting CREBBP mutations in relapsed acute lymphoblastic leukemia Cancer Research. 78 |
| Raisner R, Bainer R, Chan E, et al. (2018) Abstract 1483: Targeting oncogenic enhancer activity with a small-molecule CBP/P300 bromodomain inhibitor Cancer Research. 78: 1483-1483 |
| Romero FA, Murray JM, Lai KW, et al. (2017) GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). Journal of Medicinal Chemistry |
| Crawford TD, Romero FA, Lai KW, et al. (2016) Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. Journal of Medicinal Chemistry |
| Conery AR, Centore RC, Neiss A, et al. (2016) Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 5 |
| Keller PJ, Conery AR, Centore RC, et al. (2016) Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma Cancer Research. 76: 4749-4749 |
| Rago F, Gascoigne KE, Cheeseman IM. (2015) Distinct organization and regulation of the outer kinetochore KMN network downstream of CENP-C and CENP-T. Current Biology : Cb. 25: 671-7 |